Ray Therapeutics, a clinical-stage biotechnology company developing optogenetic gene therapies for vision restoration, has appointed Michael Murtagh as Chief Regulatory Officer. With more than 20 years of experience in regulatory affairs, Murtagh has led multiple Investigational New Drug Applications (INDs), Clinical Trial Applications (CTAs) and marketing applications across a range of indications, spanning therapeutic areas including oncology, cardiovascular disease, neurology and inborn er...